References

clinvest

Качественная клиническая практика

Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice

2588-05192618-8473

ООО «Издательство ОКИ

clinvest-127

Research Article

КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ

CLINICAL TRIALS

Комбинированные конечные точки в клинических исследованиях: обзор публикаций

Явелов

И. С.

ФГБУ «НМИЦ профилактической медицины» МЗ РФ; ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» МЗ РФRussian Federation

2010

05062018

013953

2018

Явелов И.С.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.clinvest.ru/jour/article/view/127

комбинированные конечные точки клинические исследования

References1

. Neaton JD, Gray G, Zuckerman BD, et al. Key issues in end point selection for heart failure trials: composite end points . J Cardiac Failure 2005; 11: 567–75

. International Conference on Harmonisation . ICH harmonized tripartite guideline E9: statistical principals for clinical trials [online] . Available from URL: http://www .ich .org/LOB/media/MEDIA485 .pdf [Accessed 2007 Jan 23]

. Hamilton M. A rating scale for depression . J Neurol Neurosurg Psychiat 1960; 23: 56–62

. American College of Rheumatology . Subcommittee on Rheumatoid Arthritis Guidelines . Guidelines for the management of rheumatoid arthritis: 2002 update . Arthritis Rheum 2002; 46: 328–46

. Lubsen J, Kirwan B-A. Combined endpoints: can we use them? Stat Med 2002; 21: 2959–70

. Rappaport M. The disability rating and coma/near-coma scales in evaluating severe head injury . Neuropsychol Rehabil 2005; 15: 442–53

. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid . Dermatologica 1978; 157: 238–44

. Chi GYH. Some issues with composite endpoints in clinical trials . Fundam Clin Pharmacol 2005; 19: 609–19

. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet 2002; 359: 995–1003

. Cohn JN, Tognoni G, for the Valsartan Heart Failure Investigators . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . N Engl J Med 2001; 345: 1667–75

. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial . JAMA 2001; 285: 1711–8

. Gerstein HC, Yusuf S, Pogue J, et al. for the DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial . Lancet 2006; 368: 1096–105

. Dormandy JA, Charbonnel B, Eckland DA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macro Vascular Events): a randomised controlled trial . Lancet 2005; 366: 1279–89

. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med 2001; 345: 851–60

. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients . Transplantation 2004; 78: 1532–40

. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial . Ann Intern Med 1995; 123: 241–9

. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial . J Clin Oncol 1999; 17: 846–54

. Beasley CM, Sutton VK, Hamilton SH, et al. The olanzapine relapse prevention study group: a double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse . J Clin Psychopharmacol 2003; 23: 582–94

. Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289: 2554–9

. Cannon CP. Clinical perspectives on the use of composite endpoints . Control Clin Trials 1997; 18: 517–29

. Fox KAA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial . Lancet 2002; 360: 743–51

. The TIME Investigators . Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial . Lancet 2001; 358: 951–7

. Torp-Pederson C, Moller M, Bloch-Thomsen P, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction . N Engl J Med 1999; 341: 857–65

. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, et al. Validity of composite endpoints in clinical trials . BMJ 2005; 330: 594–6

. Lauer MS, Topol AJ. Clinical trials: multiple treatments, multiple end points, and multiple lessons . JAMA 2003; 289: 2575–7

. The ESPRIT Study Group . Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial . Lancet 2006; 367: 1665–73

. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT . Lancet 1997; 349: 675–82

. Gottlieb SS. Dead is dead: artificial definitions are no substitute . Lancet 1997; 349: 662–3

. Committee for Proprietary Medicinal Products (CPMP) . Points to consider on multiplicity issues in clinical trials . CPMP/EWP/908/99 . London, 19 Dec 2002 [online] . Available from URL: http://www .emea .europa .eu/pdfs/human/ewp/090899 en .pdf [Accessed 2007 Jan 23]

. Niewoehner DE, Erbland ML. Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease . N Engl J Med 1999; 340: 1941–7

. Echt DS, Liebson PR, Mitchell IB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial . N Engl J Med 1991; 324 r 781–8

. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial . Circulation 1996; 94: 2793–9

. Lubsen J. Exercise testing as outcome in congestive heart failure trials: design considerations when interpreting results . Drugs 1994; 47: 25–30

. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation . Control Clin Trials 1997; 18: 530–45

. UK Prospective Diabetes Study (UKPDS) Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 . BMJ 1998; 317: 703–13

. McGuire DK, Califf RM. Diabetes and cardiovascular disease: current opinions and future directions . Am Heart J 1999; 138 (5 Pt 1): S327–9

. FDA, Center for Drug Evaluation and Research (CDER) and Center for Biologies Evaluation and Research (CBER) . Draft guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologies . April 2005 [online] . Available from URL: http://www .fda . gov/cder/Guidance/6592 dft .pdf [Accessed 2007 Jan 23]

. Johnson JR, Williams G, Pazdur R, et al . End points and United States Food and Drug Administration approval of oncology drugs . J Clin Oncol 2003; 21: 1404–11

. Schulz KF, Grimes DA. Multiplicity in randomized trials 1: endpoints and treatments . Lancet 2005; 365: 1591–5

. Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, et al. Problems with the use of composite endpoints in cardiovascular trials: systematic review of randomised controlled trials . BMJ 2007; 334: 786–8

. Yudkin JS. The DREAM trial [comment] . Lancet 2006; 368: 2049–50

. Nissen SE. The DREAM trial [comment] . Lancet 2006; 368: 2049

. Hallstrom AP, Litwin PE, Weaver WD. A method of assigning scores to the components of a composite outcome: an example from the M1 TI trial . Control Clin Trials 1992; 13: 148–55

. Neaton JD, Wentworth DN, Rhame F, et al. Considerations in choice of a clinical endpoint for AIDS clinical trials . Stat Med 1994; 13: 2107–25

. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder . Divalproex Maintenance Study Group . Gen Psychiatry 2000; 57: 481–9

. Bristow MR, Saxon LA, Boehmer J, et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators . Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure . N Engl J Med 2004; 350: 2140–50

. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) . Lancet 2000; 356: 366–72

. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORD1 L) study . Lancet 2000; 356: 359–65

. Committee for Medicinal Products for Human Use (CHMP) . Guideline on data monitoring committees: EMEA/CHMP/EWP/5872/03 . London, 27 Jul 2005 [online] . Available from URL: http://www .emea .europa .eu/pdfs/human/ewp/587203 en .pdf [Accessed 2007 Jan 23]

. FDA, Center for Drug Evaluation and Research (CDER), Center for Biologies Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH) . Draft guidance for clinical trial sponsors . On the establishment and operation of clinical trial data monitoring committees . 2001 Nov [online] . Available from URL: http://http://www .fda .gov/cber/gdlns/clindatmon .pdf [Accessed 2007 Jan 23]

. The Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group . A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomized, dose-finding study . Eur Heart J 1997; 18: 1416–25

. Naslund U, Grip L, Fischer-Hansen J, et al. The impact of an end-point committee in large multicentre, randomized, placebo-controlled clinical trial . Eur Heart J 1999; 20: 771–7

. Mahaffey KW, Roe MT, Dyke CK, et al. Second Platelet Hb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial: misreporung of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial . Am Heart J 2002; 143: 242–8

. Mahaffey KW, Harrington RA, Akkerhuis M, et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial . Curr Control Trials Cardiovasc Med 2001; 2: 180–6

. Skyler JS. PROactive results overstated and misleading . DOC News 2005; 2: 4

. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive) . Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5 .238 patients . Diabetes Care 2004; 27: 1647–53

. The PROactive Study Executive Committee and Data and Safety Monitoring Committee . PROactive study . Lancet 2006; 367: 982

. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) . Lancet 2003; 362: 782–8

. Montori VM, Guyatt GH. Intention-to-treat principle . CMAJ 2001; 165: 1339–41

. Skali H, Pfeffer MA, Lubsen J. Variable impact of combining fatal and nonfatal endpoints in heart failure trials . Circulation 2006; 114: 2298–303

. Lubsen J, Poole-Wilson PA. The DREAM trial [comment] . Lancet 2006; 368: 2050

. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial . N Engl 1 Med 2005; 352: 1092–102

. Lagakos SW. Time-to-event analyses for long-term treatments: the APPROVe Trial . N Engl J Med 2006; 355: 113–7

. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial . Lancet 2004; 364: 849–57

. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction . N Engl J Med 2004; 351: 2481–8

. Chen YHJ, DeMets DL, Lan KKG. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis . Control Clin Trials 2003; 24: 16–27

. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure . N Engl J Med 1996; 334: 1349–55

. Fisher LD, Moye LA. Carvedilol and the Food and Drug Administration (FDA) approval process: an introduction . Control Clin Trials 1999; 20: 1–15

. Fisher LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing . Control Clin Trials 1999; 20: 16–39

. Kleist P. Stopping a trial early for treatment benefit: pros and cons . Appl Clin Trials 2007; Jan: 34–7

. Montori VM, Devereaux PJ, Adhikari NKJ, et al. Randomized trials stopped for benefit: a systematic review . JAMA 2005; 294: 2203–9

. The CAPRICORN Investigators . Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRIC randomised trial . Lancet 2001; 357: 1385–90

. Brown DL, Fann CSJ, Chang CJ. Effect of glycoprotein Hb/IIIa inhibitors с individual components of composite endpoints used in clinical trials of un: angina and non-Q-wave myocardial infarction . Cardiovasc Drugs Ther: 14: 253–8

. Freemantle N, Calvert M. Composite and surrogate outcomes in randomization controlled trials . BMJ 2007; 334: 75,6–7

. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in myocardial infarction trial (STAT) . J Am Coll Cardiol 2001; 37: 985–91

. Temple R. Multiple endpoints: statistical framework for clinical decision . Drug Information Association 39 th Annual Meeting; 2003 Jun 15–19 Antonio (TX) .

. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT state me reporting randomized trials: explanation and elaboration . Ann Intern Med 134: 663–94

The authors declare that there are no conflicts of interest present.